Study guide
11.2 Protocol Submission, Approval & Amendment Processes
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
11.2 Protocol Submission, Approval & Amendment Processes
Key Takeaways Explain This Topic AI
ICH E6(R3) Annex 1 section 1.4.6 requires that no participant be enrolled before the IRB/IEC issues its documented approval or favourable opinion of the trial.
Section 1.4.7 prohibits initiating any deviation from or change to the protocol without prior documented IRB/IEC approval of an appropriate amendment, with two narrow exceptions.
The two exceptions are changes necessary to eliminate immediate hazards to participants, and changes involving only logistical or administrative aspects where regulatory requirements allow.
Where a deviation is made to eliminate an immediate hazard, the investigator informs the sponsor promptly and reports the hazard, the change made and any proposed amendment to the IRB/IEC and regulatory authorities.
In ICH E6(R3) the term "protocol" refers to the protocol and its amendments, and a protocol amendment is defined simply as a documented description of a change to a protocol.
Last updated: August 2026
Protocol Submission, Approval & Amendment Processes
Quick Reference: In the ICH E6(R3) glossary, "the term 'protocol' refers to protocol and protocol amendments" , and a protocol amendment is "a documented description of a change(s) to a protocol." There is no such thing as an informal amendment. If the change is not documented and approved, it is not an amendment — it is a deviation.
Why this is tested
The ACRP-CP Exam Content Outline lists 2G, "Protocol submission, approval, and amendment processes" in Domain 2, and the task statements include "Coordinate protocol and/or protocol amendments through appropriate approval processes (e.g., IRB/IEC, sponsor, regulatory authority)" and "Implement the administrative and/or clinical tasks for protocol amendments."
Part 1 — Getting to first enrolment
Two approval streams run in parallel and both must complete before anyone is enrolled. SPONSOR develops protocol (Appendix B contents)
- │
- ┌───────────────┴────────────────┐
- │ │
- REGULATORY STREAM ETHICS STREAM
- Annex 1 §3.8.1 Annex 1 §1 and §3.8.2
- Sponsor (or sponsor and Submission by investigator/
- investigator) submits any institution or sponsor per
- required application to the applicable requirements
- appropriate authority for
- review, acceptance and/or IRB/IEC review of protocol,
- permission to begin ICF, recruitment material,
- IB, investigator qualifications
- │ │
- Permission / acceptance Documented approval or
- to begin the trial favourable opinion
- └───────────────┬────────────────┘
- │
- Both complete + contract executed + site greenlight
- │
- FIRST PARTICIPANT ENROLLED
Annex 1 section 1.4.6 is categorical: the IRB/IEC must specify "that no participant should be enrolled in a trial before the IRB/IEC issues its documented approval/favourable opinion of the trial."
Note the word documented . A chair's verbal assurance, an email saying "it went through", or minutes not yet issued are not approval. The site holds a dated approval letter identifying the exact protocol version and the exact consent form version.
- What the IRB/IEC reviews
- The protocol and any amendments
- The informed consent form and any assent documents, in the languages to be used
- Recruitment materials — advertisements, scripts, screening questionnaires
- The Investigator's Brochure or equivalent product information
- Investigator qualifications, typically the current curriculum vitae
- Participant payment and reimbursement arrangements
- Any participant-facing materials such as diaries and instruction sheets
- Information on funding sources and conflicts of interest
- Version control is the site's job
Every approved document has a version number and a date . The consent form in the drawer must be the version named in the approval letter. Site staff should be able to answer, without hesitation, which protocol version is currently in force, which consent version each participant signed, and when each was approved.
- Part 2 — Amendments
- The default rule and its two exceptions
Annex 1 section 1.4.7 requires the IRB/IEC to specify "that no deviations from or changes to the protocol should be initiated without prior documented IRB/IEC approval/favourable opinion of an appropriate protocol amendment except when necessary to eliminate immediate hazards to the participants or, in accordance with applicable regulatory requirements, when the change(s) involves only logistical or administrative aspects of the trial."
Read as a decision:
Situation May you act before approval?
- Ordinary change of any kind No. Prior documented approval of an amendment is required
- Change necessary to eliminate an immediate hazard to participants Yes — act first, then report
Change involving only logistical or administrative aspects, where regulatory requirements permit Yes , per applicable requirements
Exam Watchout: The immediate-hazard exception is narrow and is about hazard , not inconvenience, recruitment pressure or operational difficulty. A participant developing a dangerous laboratory abnormality who needs a dose held outside the protocol's rules is an immediate hazard. A site that cannot recruit under the current criteria is not.
The immediate-hazard pathway
Annex 1 section 2.5.4: the investigator "should follow the protocol and deviate only where necessary to eliminate an immediate hazard(s) to trial participants. In case of deviations undertaken to eliminate immediate hazard to trial participants, the investigator should inform the sponsor promptly."
Annex 1 section 2.5.5: the investigator "should report information on the immediate hazard, the implemented change and the subsequent proposed protocol amendment, if any, to the IRB/IEC and, where applicable, regulatory authorities." Immediate hazard identified
- │
- 1. ACT to protect the participant — do not wait for approval
- │
- 2. DOCUMENT in the source record: the hazard, what was done, the clinical rationale
- │
- 3. INFORM THE SPONSOR PROMPTLY (§2.5.4)
- │
4. REPORT to the IRB/IEC and, where applicable, regulatory authorities:
- the hazard · the change implemented · the proposed amendment, if any (§2.5.5)
- │
- 5. AMEND the protocol if the change needs to become permanent
- Substantial versus administrative changes
Type Typical content Route
Substantial — affects participant safety, rights or well-being, or the scientific value of the trial New or changed eligibility criteria; dose, schedule or route changes; new procedures; changed primary endpoint; new safety monitoring; sample size change; extended duration Full IRB/IEC review; usually regulatory notification/submission; consent form usually revised; often registry update
Administrative / logistical Typographical corrections; updated sponsor contact details; change of monitor; formatting; corrected page numbering Notification or expedited handling per the IRB/IEC's own procedures
Annex 1 section 1.4.5 permits the IRB/IEC to provide "expedited review and approval/favourable opinion of minor change(s) in ongoing trials" that already hold its approval, in accordance with applicable regulatory requirements. The IRB/IEC decides whether a change is minor — the sponsor's or site's label does not bind it.
Design out the need for amendments
Appendix B makes a point worth carrying into practice: "Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial."
A protocol that specifies "day 28" generates deviations; one that specifies "day 28 ± 3 days" does not, without any loss of scientific integrity. This is Principle 8 — clear, concise and operationally feasible — applied at the drafting stage.
Part 3 — The amendment cascade
Approving an amendment is the beginning of the work, not the end. Each of the following must be handled and evidenced:
- Task Detail
- Regulatory submission or notification Where the change requires it under applicable requirements
- IRB/IEC approval Dated, identifying the new protocol version
- Consent form revision New version approved before use
Re-consent decision Do currently enrolled participants need to be re-consented, and by when? Ongoing participants affected by a new risk or procedure normally must be
- Registry update Where the amendment changes design, endpoints, eligibility or duration
- Staff retraining Documented training on the new version, filed as an essential record
System updates eCRF, edit checks, IRT, laboratory manual, source worksheets — Annex 1 4.3 requires trial-specific systems, including updates resulting from protocol amendments , to be handled under the computerised-systems controls
- Supplies and logistics New kits, revised diaries, changed drug supply
- Essential records Signed protocol and subsequent amendments retained per Appendix C
Effective date discipline The amendment applies from its approval date at that site; participants seen before it continue under the prior version until re-consented
Exam Watchout: The most common site failure is implementing an amendment on the date the sponsor issued it rather than the date the local IRB/IEC approved it . Sites in a multicentre trial will lawfully be running different protocol versions for a period, and that is correct — each site follows the version approved for it.
Realistic exam scenario
Scenario: A sponsor emails all sites on 3 March with amendment 4, which adds a mandatory electrocardiogram at every visit after two participants elsewhere developed QTc prolongation, and lowers the maximum permitted dose. The email says "effective immediately." A coordinator schedules ECGs from the following day. Her site's IRB approves amendment 4 on 24 March. Between 4 and 24 March, six participants attend visits: five receive the new ECG, and one is dose-reduced under the new maximum.
Evaluation — the two changes are not the same:
The dose reduction is defensible if it was necessary to eliminate an immediate hazard to that specific participant. Under section 2.5.4 the investigator may deviate for that reason, must inform the sponsor promptly, and under 2.5.5 must report the hazard, the change and the proposed amendment to the IRB/IEC and, where applicable, regulatory authorities. The clinical rationale must be documented in the source record.
Performing the five additional ECGs before local approval is not covered by either exception. An ECG is a study procedure the participants did not consent to and the IRB had not approved. "The sponsor said effective immediately" carries no weight against section 1.4.7 — the sponsor cannot approve on the IRB's behalf.
Correct actions: stop implementing amendment 4 until the local approval date; document the five pre-approval ECGs as protocol deviations and report them to the IRB/IEC and sponsor; assess whether any participant was placed at risk or incurred an unconsented procedure; determine whether the revised consent form requires re-consent of currently enrolled participants and complete it before their next visit; confirm the registry entry reflects the changed design; document retraining on version 4; and raise a CAPA establishing that at this site amendments take effect on the local IRB approval date , communicated to the sponsor as feedback on its "effective immediately" language.